Latest Biotech News

Krystal Biotech disclosed early clinical signals for a mutation‑agnostic approach to cystic fibrosis, reporting data that the company says support a direct move into a pivotal trial. The firm...

The Biotechnology Innovation Organization (BIO) launched the BIO Investment Council to strengthen ties between investors and early‑stage biotechs and to improve private capital formation. The...

Aktis Oncology priced its initial public offering, raising $318 million in what market watchers called the first meaningful biotech IPO of 2026. The upsized offering was led in part by a $100...

Eli Lilly agreed to acquire Ventyx Biosciences for about $1.2 billion in cash to add oral NLRP3 inhibitors to its inflammation pipeline. The deal gives Lilly clinical‑stage assets targeting the...

Media reports say Merck is in discussions to acquire Revolution Medicines in a transaction valued between $28 billion and $32 billion. Sources cited by the Financial Times indicated negotiations...

Illumina appointed former NHGRI director Eric Green as chief medical officer, effective Feb. 2. Green leaves a long public‑sector tenure to join the sequencing leader as it seeks to accelerate...

Boltz launched as a public benefit corporation out of MIT CSAIL with a $28 million seed round led by Amplify, a16z and Zetta, aiming to make high‑accuracy AI models and drug‑design tools broadly...

A startup co‑founded by gene‑editing experts including Fyodor Urnov, with advisory support from Jennifer Doudna, launched Aurora Therapeutics after a $16 million seed from Menlo Ventures. The...

EpiBiologics closed a $107 million Series B to advance its first‑in‑class protein‑degrading antibody programs, including lead candidate EPI‑326 targeting EGFR for non‑small cell lung and...

Cellares signed a collaboration with City of Hope to evaluate the Cell Shuttle manufacturing platform and Cell Q quality‑control automation for City of Hope’s glioblastoma CAR‑T program. The...

GlaxoSmithKline secured a non‑exclusive license to Noetik’s cancer foundation models with an upfront payment of $50 million, marking a new commercial structure for AI assets in drug discovery. The...

The US military’s health plan, Tricare, added coverage for Guardant Health’s Shield blood‑based colorectal cancer screening test, making the FDA‑approved assay available with no copay to...

Aktis Oncology priced an upsized initial public offering that raised about $318 million, marking the first biotech IPO of 2026. The Boston-based radiopharmaceutical developer will trade on Nasdaq...

Eli Lilly agreed to acquire Ventyx Biosciences for approximately $1.2 billion in cash to add oral NLRP3 inhibitors to its pipeline. Lilly said the acquisition strengthens its inflammation and...

OpenAI launched ChatGPT Health and pushed offerings for hospitals and health systems, bringing its conversational LLM directly into clinical and administrative workflows. The company positioned...

Aurora Therapeutics, cofounded by leaders from the Baby KJ personalized-CRISPR effort and backed by Menlo Ventures, launched with seed funding to pursue grouped or 'umbrella' regulatory pathways...

Boltz, a Massachusetts PBC spun out of MIT CSAIL research, launched Boltz Lab and open-source biomolecular AI models to accelerate structural prediction and therapeutic design. The company opened...

Parabilis Medicines closed a $305 million Series F financing to advance its corkscrew-shaped peptide platform and lead candidate zolucatetide into late-stage testing. The round, one of the largest...

Orca Bio raised $250 million in fresh financing to support the commercial launch of its T-cell therapy for complications from allogeneic stem cell transplants. The funds will be used to scale...

Cellares and City of Hope struck a collaboration to evaluate automated manufacturing and QC for City of Hope’s investigational CAR T program targeting glioblastoma. The agreement will test...